Современные принципы антибактериальной терапии тяжелых и жизнеугрожающих бактериальных инфекций


Стецюк О.У., Андреева И.В.

В представленном обзоре рассмотрены современные принципы антибактериальной терапии тяжелых и жизнеугрожающих бактериальных инфекций, дано обоснование каждого из положений на основании результатов проведенных клинических исследований. Использование современной стратегии антибактериальной терапии в клинической практике не только позволяет добиться улучшения клинических исходов лечения пациентов с различными нозологическими формами инфекций, но и обеспечивает существенный экономический эффект.

Литература





  1. Sandiumenge A, Diaz E, BodeM, et al. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of “The Tarragona Strategy”. Int Care Med 2003;29: 876–83.

  2. Vidaur L, Sirgo G, Rodriguez AH, et al. Clinical approach to the patient with suspected ventilator-associated pneumonia. Respir Care 2005; 50:965–74.

  3. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589–96.

  4. Lebel MH, McCracken GH. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989;83:161–17.

  5. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080–84.

  6. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничные пневмонии у взрослых: практические рекомендации по диагностике, лечению и профилактике // КМАХ. 2006. № 1. С. 54–86.

  7. Hutt E, Kramer AM. Evidence-based guidelines for management of nursing home-acquired pneumonia. J Fam Pract 2002;51:709–16.

  8. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. Clin Infect Dis 2004;39:1267–84.

  9. Miner JR, Heergaard W, Mapes A, et al. Presentation, time to antibiotics, and mortality in patients with bacterial meningitis at an urban county medical center. J Emerg Med 2001;21:387–92.

  10. Lu CH, Huang CR, Chang WN, et al. Community-acquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors. Clin Neurol Neurosurg 2002;104:352–58.

  11. Деллинджер Р.Ф., Карле Ж.М., Мазур Г. и др. Рекомендации по ведению пациентов с тяжелым сепсисом и септическим шоком // КМАХ. 2005. № 3. С. 208–234.

  12. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике // КМАХ. 2005. № 1. С. 4–31.

  13. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37(8):997–1005.

  14. Shorr AF, Sherner JH, Jackson WL, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2005;33:46–53.

  15. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111(3):676–85.

  16. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987–94.

  17. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146–55.

  18. Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med 2004;32: 2207–18.

  19. Micek ST, Isakow W, Shannon W, et al. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Pharmacotherapy 2005;25:26–34.

  20. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(1):196–200.

  21. Kollef MH, Bock KR, Richards RD, et al. The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. Ann Intern Med 1995;122:743–48.

  22. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486–94.

  23. Valles J, Rello J, Ochagavia A, et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003;123:1615–24.

  24. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49(2):760–66.

  25. Lodise TP, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007;51:3510–15.

  26. Neu HC. General concepts on the chemotherapy of infectious diseases. Med Clin North Am 1987;71(6):1051–64.

  27. Namias N, Samiian L, Nino D, et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000;49:638–45.

  28. WHONET Software. Available from: http://www.who.int/drugresistance/whonetsoftware/en/.

  29. World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance. WHO/CDS/CSR/DRS/2001.2a. Geneva, Switzerland; 2001.

  30. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913–20.

  31. Shurland S, Zhan M, Bradham DD, et al. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007;28(3):273–79.

  32. Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60:855–63.

  33. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531–39.

  34. Решедько Г.К., Рябкова Е.Л., Кречикова О.И. и др. Антибиотикорезистентность грамотрицательных возбудителей нозокомиальных в отделениях реанимации и интенсивной терапии России // КМАХ. 2008. № 1 (в печати).

  35. Cardo D, Horan T, Andrus M, et al. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. A report from the NNIS System. Am J Infect Control 2004;32:470–85.

  36. Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным препаратам в России. Практическое руководство по антиинфекционой химиотерапии / Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. Смоленск, 2007. С. 32–46.

  37. Mouton YJ, Beuscart C. Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995;36(Suppl. A):145–56.

  38. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38(6):1309–13.

  39. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355: 2619–30.

  40. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67: 1027–52.

  41. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004;32(11): 2183–90.

  42. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588–98.

  43. Страчунский Л.С., Муконин А.А. Влияние фармакодинамики различных классов антибактериальных препаратов на режимы их дозирования // Антибиотики и химиотерапия. 2000. № 4. С. 40–44.

  44. Masterton RG, Kuti JL, Turner PJ, et al. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 2005;55(1):71–77.

  45. Drusano G. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(Suppl. 1):S42–50.

  46. Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40:219–23.

  47. Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2005;5(9):581–89.

  48. Ягудина Р.И., Куликов А.Ю., Крысанов И.С. Фармакоэкономический анализ стартовых эмпирических режимов антибактериальной терапии тяжелых нозокомиальных инфекций в отделении реанимации и интенсивной терапии // РМЖ. 2006. № 21. С. 1505–1511.

  49. Turner PJ. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Diagn Microbiol Infect Dis 2006;56:341–44.



Бионика Медиа